New therapeutic approaches for endometriosis besides hormonal therapy. 
Endometriosis is a common gynecologic disease that frequently leading to chronic pelvic pain, severe dysmenorrhea, and subfertility.  As first-line hormonal treatment can interfere with ovulation and may cause recurrent pelvic pain, exploration of new non-hormonal therapeutic approaches becomes increasingly necessary.  This review aimed to evaluate the pre-clinical and clinical efficacy and safety of non-hormonal treatment for endometriosis DATA SOURCES:: Databases including PubMed, Embase, Cochrane Library, SINOMED, ClinicalTrials.gov, and Google Scholar were searched up to October 2019, using search terms "endometriosis" and "non-hormonal therapy."  Twenty-four articles were reviewed for analysis, including nine animal studies and 15 human trials; all were published in English.  Twenty-four articles were identified, including 15 human trials with 861 patients and nine animal studies.  Some agents have been evaluated clinically with significant efficacy in endometriosis-related pelvic pain and subfertility, such as rofecoxib, etanercept, pentoxifylline, N-palmitoylethanolamine, resveratrol, everolimus, cabergoline (Cb2), and simvastatin.  Other drugs with similar pharmacological properties, like parecoxib, celecoxib, endostatin, rapamycin, quinagolide, and atorvastatin, have only been tested in animal studies.  Clinical data about most of the non-hormonal agents are not sufficient to support them as options for replacement therapy for endometriosis.  In spite of this, a few drugs like pentoxifylline showed strong potential for real clinical application.